Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05766098

Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY

Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs). The evaluation of the PTC mutational profile is crucial for the definition of the prognosis and for predicting the effects of targeted and personalized therapies. Molecular characterization by mass spectrometry (Mass ARRAY) allows the search for multiple mutations in a single experiment, in a sensitive, fast and economic way. A Mass ARRAY platform (PTC-MA) was developed, capable of identifying the presence of the most common somatic point mutations and rearrangements in PTC (Pesenti et al., Endocrine 2017). The aim of the study is to characterize the mutational profile of a large series of papillary thyroid carcinomas (PTC). Tumor samples will be analyzed using our PTC-MA platform. The molecular profile of PTCs will be correlated with the clinical and prognostic characteristics of the patients.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Istituto Auxologico Italiano

Milan, MI, 20145, Italy

Location status: Recruiting

Location contact

Gianfranco Parati, MD

CONTACT

[email protected]

0261911 ext. 2890

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with papillary thyroid cancer
  • patients whose tumor tissue can be recovered for genetic analysis

Exclusion criteria

  • patients who did not give consent
  • patients lost to follow-up
  • tumor samples not suitable for genetic analysis

Treatment and study plan

Genotyping

Genetic

Characterization of genetic profile of tumor tissues

Primary outcomes

  1. Mutational profile of PTCs

    Time frame: years 1-8

    The mutational profile of about 600 PTCs will be characterized and correlate with the clinical characteristics and patient outcomes

Study contacts

Contact information is provided by the study sponsor or research team.

Marina Muzza, PhD

CONTACT

[email protected]

+390261191 ext. 2432

Sponsors and collaborators

Lead sponsor

Istituto Auxologico Italiano

Other

Registry information

Official study title

Caratterizzazione Del Profilo Mutazionale Nel Tumore Papillare Della Tiroide Tramite Tecnologia Mass-ARRAY

Acronym: PTC-ARRAY

Important dates

Study start
2019
Primary completion
2027
Study completion
2027
First posted
Mar 13, 2023
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.